Skip to content

Developing treatments for patients with underserved CNS disorders

Bionomics is a global, clinical-stage biopharmaceutical company developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious Central Nervous System (“CNS”) disorders.

 

Corporate Presentation

Targeting Distinct CNS Conditions with Neurotransmitter Imbalance

Bionomics has a pipeline of novel therapeutic candidates targeting the treatment of serious central nervous system disorders for which there is a large unmet medical need.

Development of our pipeline is accelerated through our partnering strategy, which allows multiple and diverse programs to be optimally developed.

 

Learn More

Get in touch

For latest Bionomics announcements:

Contact us